| |
| |
|
| Insider
Information: |
Labrucherie Gil M |
| Relationship: |
Chief Financial Officer |
| City: |
San Carlos |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
319,155 |
|
|
Indirect Shares
|
94,335 |
|
|
| Direct
Value |
$576,586 |
|
|
|
Indirect Value
|
$320,380 |
|
|
| Total
Shares |
413,490 |
|
|
| Total
Value |
$896,965 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -181.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLRN |
Acelyrin, Inc. |
Interim CFOOfficer |
• – – |
2023-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,250 |
|
% |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2008-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,122 |
2,369 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2009-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2011-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
7,417 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
8,757 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
34,421 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2016-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
71,629 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
83,414 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
103,216 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
121,266 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
135,294 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
227,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,150 |
259,159 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
266,973 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,150 |
280,831 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
52,950 |
309,182 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
330,353 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Financial Officer |
• – – |
2023-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
40,763 |
40,763 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2008-11-14 |
4 |
S |
$4.37 |
$1,752 |
D/D |
(401) |
1,968 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2009-05-12 |
4 |
S |
$5.57 |
$2,200 |
D/D |
(395) |
2,662 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$9,858 |
D/D |
(827) |
6,590 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-05-17 |
4 |
S |
$13.58 |
$11,353 |
D/D |
(836) |
7,921 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2016-11-16 |
4 |
S |
$13.96 |
$23,090 |
D/D |
(1,654) |
51,129 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$30,997 |
D/D |
(2,359) |
69,270 |
0 |
- |
|
104 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
